Nicole Tepe, Ph.D.
With over a decade of patent experience, both as outside counsel and as in-house counsel for a leading consumer products company, Nicole has significant expertise in patent drafting and prosecution for biological and medical technologies, including methods of treatment, diagnostics, pharmaceutical compositions, and delivery of pharmaceuticals. In addition, Nicole assists clients in building a patent portfolio, strategically protecting their inventions, and improving the likelihood that new technologies and products are successfully commercialized.
Memberships & Affiliations
- Ohio State Bar
- United States Patent and Trademark Office
- Cincinnati Bar Association
- Myriad Supreme Court Decision - cDNA, but not Isolated DNA, is Patent Eligible Subject Matter
- Supreme Court Rules Law of Nature Not Patentable in Mayo v. Prometheus
- ALP: As an innovative life sciences company, what are my primary intellectual property concerns?
- DNA Patents: More Than Someone 'Owning Your Genes'
Non-FBT Publications and Events
Speaker: Women’s Economic Outreach Organization (WEDO), 2006
Adjunct Lecturer: University of Cincinnati, Media Law, Fall 2005 and 2006
Nicole has contributed to PatentBaristas.com and has authored several publications including:
Intellectual Property Publications:
Author: “DNA Patents: More than Someone Owning Your Genes,” FDLI 2007
Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW 2nd. Early and delayed consequences of b2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000 Apr 11; 101(14): 1707-14.
Tepe NM, Liggett SB. Functional receptor coupling to Gi is a mechanism of agonist-promoted desensitization of the b2-adrenergic receptor. Journal of Receptor Signal Transduction Research 2000 Jan. 20(1): 75-85.
Tepe NM, Lorenz JN, Yatani A, Dash R, Kranias EG, Dorn GW 2nd, Liggett SB. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signaling.
Biochemistry. 1999 Dec 14; 38(50): 16706-13.
Tepe NM, Liggett SB. Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of b-adrenergic receptor dysfunction in the G aq overexpressing mouse. FEBS Letters 1999 Sep 17; 458(2): 236-40.
Dorn GW 2nd, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired beta-adrenergic receptor signaling in Gaq-mediated cardiac hypertrophy and ventricular dysfunction. Molecular Pharmacology. 2000 Feb; 57(2): 278-87.
Dorn GW 2nd, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low- and high-level transgenic expression of b2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gaq-overexpressing mice. Proceedings of the National Academy of Science U S A. 1999 May 25;96(11):6400-5.
Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW 2nd, Kranias EG. Interactions between phospholamban and b-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation. 2001 Feb 13; 103(6): 889-96.